PartnershipJul 13, 2026, 07:01 AM
Veraxa Biotech Partners with Ardigen for AI-Driven Cancer Therapies
AI Summary
Veraxa Biotech announced a collaboration with Ardigen S.A., an AI-driven computational partner, to integrate artificial intelligence into its research and development. This partnership will support Veraxa's growing BiTAC® pipeline of T-cell engagers and antibody-drug conjugates by developing AI-enabled tools to guide the selection of synergistic cancer target pairs. The goal is to overcome limitations of current high-potency modalities, such as on-target, off-tumor toxicities, and achieve drug development success rates that exceed industry benchmarks.
Key Highlights
- Veraxa Biotech partnered with Ardigen S.A. to integrate AI into its R&D.
- The collaboration supports Veraxa's BiTAC® pipeline of T-cell engagers (TCEs) and antibody-drug conjugates (ADCs).
- Ardigen will develop AI-enabled tools to guide the selection of synergistic cancer target pairs.
- Veraxa's BiTAC platform uses Boolean "AND-gate" logic requiring co-expression of two distinct targets.
- This approach aims to widen the therapeutic window by sparing healthy tissues and reducing toxicity.
- AI integration seeks to improve drug development success rates beyond industry benchmarks.
- The partnership will leverage AI to analyze large datasets to identify improved dual-target combinations.
Price Impact
More from VRXA